Cargando…
Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route
Autoantigen treatment has been tried for the prevention of type 1 diabetes (T1D) and to preserve residual beta-cell function in patients with a recent onset of the disease. In experimental animal models, efficacy was good, but was insufficient in human subjects. Besides the possible minor efficacy o...
Autor principal: | Ludvigsson, Johnny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084272/ https://www.ncbi.nlm.nih.gov/pubmed/32111075 http://dx.doi.org/10.3390/ijms21051598 |
Ejemplares similares
-
Immunogenicity of autoantigens
por: Backes, Christina, et al.
Publicado: (2011) -
Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes
por: Baker, Rocky L., et al.
Publicado: (2019) -
Death, autoantigen modifications, and tolerance
por: Utz,, Paul J, et al.
Publicado: (2000) -
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
por: Mallone, Roberto, et al.
Publicado: (2011) -
Insulin as a Primary Autoantigen for Type 1A Diabetes
por: Jasinski, J. M., et al.
Publicado: (2005)